Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma
This randomized phase II trial studies how well rituximab and combination chemotherapy with
or without lenalidomide work in treating patients with newly diagnosed stage II-IV diffuse
large B cell lymphoma. Monoclonal antibodies, such as rituximab, may interfere with the
ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as
cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in
different ways to stop the growth of cancer cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Lenalidomide may stimulate the immune
system in different ways and stop cancer cells from growing. It is not yet known whether
rituximab and combination chemotherapy are more effective when given with or without
lenalidomide in treating patients with diffuse large B cell lymphoma.
Nashua,St. Johnsbury, VT
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.